317
Participants
Start Date
May 31, 2013
Primary Completion Date
August 31, 2013
Study Completion Date
September 30, 2013
Albuterol Spiromax®
Albuterol Spiromax delivers 90 mcg of albuterol base from the mouthpiece per triggered dose. Participants took doses of 2 inhalations each twice a day (morning and evening) for a total daily dose of 360 mcg. The first 45 enrolled participants constituted a subgroup who were dosed for 35 days, while most participants were dosed for 50 days.
Teva Investigational Site 10620, Phoenix
Teva Investigational Site 10637, Costa Mesa
Teva Investigational Site 10635, Huntington Beach
Teva Investigational Site 10647, Rolling Hills Estates
Teva Investigational Site 10643, San Diego
Teva Investigational Site 10644, San Jose
Teva Investigational Site 10622, Centennial
Teva Investigational Site 10634, Denver
Teva Investigational Site 10645, Wheat Ridge
Teva Investigational Site 10633, Miami
Teva Investigational Site 10640, Ormond Beach
Teva Investigational Site 10641, Overland Park
Teva Investigational Site 10636, Bethesda
Teva Investigational Site 10631, North Dartmouth
Teva Investigational Site 10646, Plymouth
Teva Investigational Site 10627, St Louis
Teva Investigational Site 10642, Bozeman
Teva Investigational Site 10613, High Point
Teva Investigational Site 10616, Raleigh
Teva Investigational Site 10618, Canton
Teva Investigational Site 10615, Oklahoma City
Teva Investigational Site 10624, Tulsa
Teva Investigational Site 10625, Eugene
Teva Investigational Site 10626, Medford
Teva Investigational Site 10632, Portland
Teva Investigational Site 10639, Charleston
Teva Investigational Site 10617, Spartanburg
Teva Investigational Site 10630, Dallas
Teva Investigational Site 10623, New Braunfels
Teva Investigational Site 10638, San Antonio
Teva Branded Pharmaceutical Products R&D, Inc.
INDUSTRY